EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Outcomes of peptic ulcer bleeding following treatment with proton pump inhibitors in routine clinical practice: 935 patients with high- or low-risk stigmata



Outcomes of peptic ulcer bleeding following treatment with proton pump inhibitors in routine clinical practice: 935 patients with high- or low-risk stigmata



Scandinavian Journal of Gastroenterology 49(10): 1181-1190



To assess rates of further bleeding, surgery and mortality in patients hospitalized owing to peptic ulcer bleeding. Consecutive patients hospitalized for peptic ulcer bleeding and treated with a proton pump inhibitor (PPI) (esomeprazole or pantoprazole) were identified retrospectively in 12 centers in Spain. Patients were included if they had high-risk stigmata (Forrest class Ia-IIb, underwent therapeutic endoscopy and received intravenous PPI ≥120 mg/day for ≥24 h) or low-risk stigmata (Forrest class IIc-III, underwent no therapeutic endoscopy and received intravenous or oral PPI [any dose]). Of 935 identified patients, 58.3% had high-risk stigmata and 41.7% had low-risk stigmata. After endoscopy, 88.3% of high-risk patients and 22.1% of low-risk patients received intravenous PPI therapy at doses of at least 160 mg/day. Further bleeding within 72 h occurred in 9.4% and 2.1% of high- and low-risk patients, respectively (p < 0.001). Surgery to stop bleeding was required within 30 days in 3.5% and 0.8% of high- and low-risk patients, respectively (p = 0.007). Mortality at 30 days was similar in both groups (3.3% in high-risk and 2.3% in low-risk patients). Among patients hospitalized owing to peptic ulcer bleeding and treated with PPIs, patients with high-risk stigmata have a higher risk of further bleeding and surgery, but not of death, than those with low-risk stigmata.

(PDF emailed within 0-6 h: $19.90)

Accession: 054812520

Download citation: RISBibTeXText

PMID: 25144754

DOI: 10.3109/00365521.2014.950694



Related references

Effect of proton pump inhibitors on the outcomes of peptic ulcer bleeding: comparison of event rates in routine clinical practice and a clinical trial. Scandinavian Journal of Gastroenterology 48(3): 285-294, 2013

Intravenous proton pump inhibitors before endoscopy in bleeding peptic ulcer with high-risk stigmata: a multicentre comparative study. Canadian Journal of Gastroenterology 19(11): 667-671, 2005

Proton pump inhibitors used as high dose intravenous infusion decrease both re-bleeding and mortality in high-risk patients with acute peptic ulcer bleeding A series of meta-analyses. Tulunay, F C , Orme, M European collaboration: Towards drug development and rational drug therapy : 104, 2003

A real world report on intravenous high-dose and non-high-dose proton-pump inhibitors therapy in patients with endoscopically treated high-risk peptic ulcer bleeding. Gastroenterology Research and Practice 2012: 858612-858612, 2012

High or nonhigh doses of proton pump inhibitors for patients with peptic ulcer bleeding?. Gastroenterology Research and Practice 2013: 803139-803139, 2013

High dose intravenous proton pump inhibition decrease both re bleeding and mortality in high risk patients with acute peptic ulcer bleeding a series of meta analyses. Digestive Disease Week Abstracts & Itinerary Planner : Abstract No W1078, 2003

High-dose vs non-high-dose proton pump inhibitors after endoscopic treatment in patients with bleeding peptic ulcer: a systematic review and meta-analysis of randomized controlled trials. Archives of Internal Medicine 170(9): 751-758, 2010

Meta-analysis: proton-pump inhibition in high-risk patients with acute peptic ulcer bleeding. Alimentary Pharmacology & Therapeutics 21(6): 677-686, 2005

High- versus low-dose proton pump inhibitors after endoscopic hemostasis in patients with peptic ulcer bleeding: a multicentre, randomized study. American Journal of Gastroenterology 103(12): 3011-3018, 2009

Oral versus intravenous proton pump inhibitors in preventing re-bleeding for patients with peptic ulcer bleeding after successful endoscopic therapy. Bmc Gastroenterology 12: 66-66, 2013

Intravenous proton pump inhibitors for peptic ulcer bleeding: Clinical benefits and limits. World Journal of Gastrointestinal Endoscopy 3(3): 49-56, 2011

Proton pump inhibitors after endoscopic hemostasis in patients with peptic ulcer bleeding. Medicinski Arhiv 63(6): 323-327, 2010

Intravenous proton pump inhibitor prior to endoscopy downstage high risk lesions in patients with bleeding peptic ulcer a multicentre comparative study. Digestive Disease Week Abstracts & Itinerary Planner : Abstract No M1804, 2003

Effect of intravenous proton pump inhibitor regimens and timing of endoscopy on clinical outcomes of peptic ulcer bleeding. Journal of Gastroenterology and Hepatology 27(9): 1473-1479, 2013

Meta-analysis: comparison of oral vs. intravenous proton pump inhibitors in patients with peptic ulcer bleeding. Alimentary Pharmacology & Therapeutics 38(7): 721-728, 2014